The patient should report any signs of liver dysfunction, such as jaundice, abdominal pain, or unusual bleeding, as an adverse effect of valproic acid (Depakene), given its potential for hepatotoxicity.
The greatest priority for a patient taking valproic acid (Depakene) is to promptly report any signs or symptoms indicative of liver dysfunction. Valproic acid has been associated with hepatotoxicity, and monitoring liver function is essential during its use. Signs of liver dysfunction include jaundice (yellowing of the skin or eyes), abdominal pain, nausea, vomiting, loss of appetite, and unusual bleeding or bruising.
Early detection and intervention are crucial to prevent severe liver damage, and reporting these symptoms promptly allows healthcare providers to assess liver function, adjust medication if necessary, or explore alternative treatments to ensure the patient's safety and well-being.